Journal of Antimicrobial Chemotherapy (2002) 49, 757-761
© 2002 The British Society for Antimicrobial Chemotherapy
Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations
1GR Micro Ltd, 7–9 William Road, London NW1 3ER, UK; 2Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, Bordeaux, France; 3Department of Clinical Microbiology, University College London Hospitals NHS Trust, London, UK
Received 25 July 2001; returned 27 December 2001; revised 16 January 2002; accepted 15 February 2002.
We investigated the in vitro development of fluoroquinolone resistance in Chlamydia trachomatis and Chlamydia (Chlamydophila) pneumoniae grown in McCoy cell monolayers in supplemented Eagle’s minimum essential medium. With C. trachomatis, initial passages at sub-inhibitory fluoroquinolone concentrations did not affect fluoroquinolone susceptibility. However, after an initial lag of 10–24 passages (depending upon the fluoroquinolone used), fluoroquinolone resistance developed rapidly. The final fluoroquinolone MIC after a total of 30 passages was >256 times the MIC of the original wild-type strain with ofloxacin or ciprofloxacin passage. Analysis of the quinolone-resistance determining regions of two quinolone-resistant C. trachomatis mutants obtained after 30 passages showed that both isolates had a single serine to isoleucine substitution at amino acid position 83 in GyrA. In stark contrast, with C. pneumoniae no reduced fluoroquinolone susceptibility could be sustained, even after 30 passages with moxifloxacin or ofloxacin. With sparfloxacin passage, some indication of resistance was observed but no viable organisms could be isolated for further investigation. It is possible that fluoroquinolone-resistant C. pneumoniae are less able to survive than wild type, which may explain why resistance does not develop readily.
* Corresponding author. Tel: +44-20-7388-7320; Fax: +44-20-7388-7324; E-mail: i.morrissey{at}grmicro.co.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Rupp, W. Solbach, and J. Gieffers Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D J. Antimicrob. Chemother., January 1, 2008; 61(1): 91 - 94. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Rupp, A. Gebert, W. Solbach, and M. Maass Serine-to-Asparagine Substitution in the GyrA Gene Leads to Quinolone Resistance in Moxifloxacin-Exposed Chlamydia pneumoniae Antimicrob. Agents Chemother., January 1, 2005; 49(1): 406 - 407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Riska, A. Kutlin, P. Ajiboye, A. Cua, P. M. Roblin, and M. R. Hammerschlag Genetic and Culture-Based Approaches for Detecting Macrolide Resistance in Chlamydia pneumoniae Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3586 - 3590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Suchland, W. M. Geisler, and W. E. Stamm Methodologies and Cell Lines Used for Antimicrobial Susceptibility Testing of Chlamydia spp. Antimicrob. Agents Chemother., February 1, 2003; 47(2): 636 - 642. [Abstract] [Full Text] [PDF]
|
|